共 50 条
- [21] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterationsANNALS OF ONCOLOGY, 2023, 34 : S63 - S64Harding, J.Perez, C.Kato, S.Sharma, M.Garmezy, B.Quah, C.Tam, B.Severson, P.
- [22] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746Tyhonas, John S.Arnold, Lee D.Cox, Jason M.Franovic, AleksandraGardiner, ElisabethGrandinetti, KathrynKania, RobertKanouni, ToufikeLardy, MatthewLi, ChunMartin, Eric S.Miller, NicholMohan, AdithiMurphy, Eric A.Perez, MichelleSoroceanu, LilianaTimple, NoelUryu, SeanWomble, ScottKaldor, Stephen W.
- [23] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene AlterationsCLINICAL CANCER RESEARCH, 2019, 25 (09) : 2699 - 2707Voss, Martin H.Hierro, CintaHeist, Rebecca S.Cleary, James M.Meric-Bernstam, FundaTabernero, JosepJanku, FilipGandhi, LeenaIafrate, A. JohnBorger, Darrell R.Ishii, NobuyaHu, YouyouKirpicheva, YuliaNicolas-Metral, ValeriePokorska-Bocci, AnnaChessex, Anne VaslinZanna, ClaudioFlaherty, Keith T.Baselga, Jose
- [24] FGFR3 mutations in benign skin tumorsCELL CYCLE, 2006, 5 (23) : 2723 - 2728Hafner, ChristianVogt, ThomasHartmann, Arndt
- [25] TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitorsMOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Sootome, HiroshiFujioka, YayoiMiura, AkihiroFujita, HidenoriHirai, HiroshiUtsugi, Teruhiro
- [26] Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusionANTICANCER RESEARCH, 2024, 44 (06) : 2393 - 2406Kawano, SatoshiKawada, Megumi ikemoriFukushima, SayoArai, YasuhitoShibata, TatsuhiroMiyano, Saori watanabe
- [27] FGFR3 mutations and FGFR3 protein overexpression in superficial bladder tumorsEUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 808 - 808Hernandez, S.Lopez-Knowles, E.Murta, C.Kogevinas, M.Lloreta, J.Carrato, A.Tradon, A.Serra, C.Malats, N.Real, F. X.
- [28] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patientsCANCER MEDICINE, 2023, 12 (07): : 7762 - 7771Xu, JianmingCui, JiuweiJiang, HaipingZeng, YanCong, Xiuyu
- [29] A phase II study evaluating the safety and efficacy of ENV-101 (taladegib) in patients with advanced solid tumors harboring PTCH1 loss of function mutationsANNALS OF ONCOLOGY, 2022, 33 (07) : S768 - S768Luke, J. J.Pendyala, S.Di Francesco, A.Kim, S.Dellamary, L.Humphreys, H.De Los Rios, M.Pitman, J.Hood, J.Hong, D. S.
- [30] MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkersJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Schwartzberg, Lee S.Spigel, David R.VanderWalde, AriZuniga, Richard MichaelHong, JasonSzado, TaniaYoo, BonginPassler, LukeWang, YongDarbonne, Walter C.Daniel, Davey